Innobia Receives IND Approval for IBR822, a First-in-Class Trop2 Antibody-Conjugated NK Cell Therapy for Solid Tumors

Recently, Imbioray (Hangzhou) Biopharmaceutical Co., Ltd., which owns the internationally innovative CAR-raNK cell technology platform, successfully obtained clinical trial implied permission (Notice No.: 2024LP00986) from the National Medical Products Administration (NMPA) for its second self-developed solid tumor drug "IBR822 Cell Injection" (Acceptance No.: CXSL2400067).

About IBR822 Cell Injection

IBR822The cell injection is the world's first non-viral and non-gene-modified treatment developed by Imbioray using its proprietary intellectual property, capable of specific targeting.TROP2Antigen and capable of killing tumor cellsNKCell（CAR-raNK）Product. Its unique specificity antibody targeting tumor antigensTROP2Through the linker andNKCells undergo chemical covalent coupling, causingIBR822With extremely high safety and powerful tumor cell killing ability.

About Imbioray

Imbioray is a clinical-stage and venture capital-backed innovative biopharmaceutical company primarily focused on the development of novel immunotherapies for advanced global oncology immunotherapy, as well as immunological diseases, chronic conditions, and CNS-related disorders. Dr. Zhenwei Miao, founder of Imbioray, returned to China in 2016 to establish the company, setting the direction for developing off-the-shelf cell therapies based on NK cells. Imbioray has four internationally unique core technology platforms that accelerate its original innovations, along with world-leading advanced processes for large-scale in vitro closed-system cultivation of NK cells. Based on its proprietary antibody-conjugated NK cell platform technology, Imbioray has developed several off-the-shelf cell therapy products, including IBR854, IBR733, and IBR822. Currently, IBR854, the world’s first cell injection for advanced solid tumors, and IBR733, the world’s first cell injection targeting acute myeloid leukemia, have both entered Phase I clinical trials. IBR822 is Imbioray's third antibody-NK cell conjugate drug, which has recently received IND tacit approval from the CDE. Imbioray also has multiple NK cell products at various stages of development.

Source: imbioray WeChat Official Account